Canada bladder cancer market is estimated to grow modestly at a CAGR of around 8.6% during the forecast period. Canada has a considerable market of bladder cancer treatment due to the increasing healthcare expenditure and significant prevalence of bladder cancer coupled with surging aging population base across the nation. It has been observed that aged people are more prone to develop bladder cancer. American Cancer Society (ASC) estimates that around 9 out of 10 people with bladder cancer are aged 55 or above. Therefore, the surging aging population base in the country is expected to fuel the bladder cancer market growth across the country. Furthermore, a significant prevalence of bladder cancer has been observed in the nation. According to Bladder Cancer Canada, bladder cancer is the fifth most common cancer in Canada, being the fourth most common among men and 12th most common among women. Moreover, an estimated 9,000 Canadians are diagnosed with bladder cancer each year, thereby representing a potential pool of the population that may demand bladder cancer drugs for treatment.
A full report of Canada Bladder Cancer Market is available at: https://www.omrglobal.com/industry-reports/canada-bladder-cancer-market
Canada bladder cancer market is segmented into cancer type, diagnosis, and treatment. Based on cancer type, the market is segmented into transitional cell bladder cancer/ urothelial carcinoma, squamous cell bladder cancer, adenocarcinoma, and other rare types (sarcomas, carcinoma in situ). Based on the diagnosis, the market is segmented into cystoscopy, biopsy, urinalysis, urine cytology, intravenous pyelogram (IVP), and others. Based on treatment, the market is segmented into chemotherapy, immunotherapy, radiation therapy, surgery, and other treatment which include targeted therapy.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/canada-bladder-cancer-market
The companies which are contributing to the growth of the Canada bladder cancer market include AstraZeneca PLC, Bristol-Myers Squibb, Co., Eli Lilly & Co., GlaxoSmithKline PLC, and Pfizer, Inc. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launches, mergers, and acquisitions, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market.
Canada Bladder Cancer Market- Segmentation
By Cancer type
- Transitional Cell Bladder Cancer/ Urothelial Carcinoma
- Squamous Cell Bladder Cancer
- Adenocarcinoma
- Other Rare Types (Sarcomas, Carcinoma in Situ)
By Diagnosis Method
- Cystoscopy
- Biopsy
- Urinalysis
- Urine Cytology
- Intravenous Pyelogram (Ivp)
- Other
By Therapy
- Chemotherapy
- Immunotherapy
- Radiation Therapy
- Surgery
- Other
